An interventional study of KSM-66 Ashwagandha® capsule and Identical Placebo capsule in Female Sexual Health, sponsored by SF Research Institute, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by SF Research Institute, Inc. · Not applicable, Interventional, and Treatment
Sexual health is a key part of a woman's overall physical, emotional, and mental well-being-even in the absence of any medical or psychological problems. It includes aspects such as sexual desire, arousal, satisfaction, and confidence in intimate relationships. Everyday factors like stress, fatigue, work-life balance, and hormonal changes can impact these areas, even in otherwise healthy women. Unfortunately, sexual wellness is often under-discussed in both clinical practice and research, especially for women who are not experiencing a diagnosed disorder.
This study is designed to explore whether Ashwagandha root extract (KSM-66), a natural herbal supplement known for its stress-reducing and vitality-enhancing properties, can help support and maintain sexual wellness in healthy adult women. Unlike treatments aimed at correcting dysfunction, this research focuses on enhancing natural sexual function-improving desire, mood, and satisfaction as part of overall health. Participants take either Ashwagandha or a placebo over several weeks, and their experiences are measured using validated tools like the Female Sexual Function Index (FSFI).
Understanding and supporting sexual wellness through natural means can improve not only intimacy and relationship satisfaction, but also self-esteem, mood, and general life satisfaction. By addressing sexual health proactively in healthy individuals, this study contributes to a more complete picture of women's health and well-being.
SF Research Institute, Inc. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
1. Female participants between 18 to 55 years of age. 2. The participate should inform their partner about the study 3. Her partner should be willing to let her participate in the study 4. Participants willing to try to have sexual intercourse regularly. 5. Participants in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least 6 months prior to the Screening Visit.
6. Participant's partner is expected to be physically present at least 50% of each month.
7. Participants who have used a medically acceptable method of contraception for at least 3 months before the baseline Visit (Visit 1) and continue to use that medically acceptable method of contraception during the trial.
8. Participants who are reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them as per investigator's opinion.
9. Participants or LAR can and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements.
10. Participants having sufficient understanding to communicate effectively with the investigator and are willing to discuss their sexual functioning with the investigative staff.
11. Participants who are willing to have 4 or more attempts of sexual intercourse each month.
Exclusion Criteria:
1. Participants who are not willing to take an investigational product. 2. Any acute illness which may hamper the study participation as per principal investigator discretion at the time of enrolment.
3. Participants having any clinically significant medical history, medical finding or an on- going medical or psychiatric condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol.
4. Individuals participating in any other studies, including macro/micro/any other forms of dietary supplements/multivitamins or disease-specific oral nutrition supplements (for improving the sexual function during the 3 months prior to study commencement).
5. Participants having a history of hypersensitivity reactions (i.e., allergic or oversensitivity to usual doses).
6. Participants with current alcohol or drug addiction or with a history of drug dependence or abuse within the past one year.
7. Participants who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the Subjects response to treatment.
8. Participants who have entered the menopausal transition or menopause or have had a hysterectomy.
9. Participants with findings of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female genital organs, at the Screening Visit.
10. Participants who are breastfeeding or have breastfed within the last 6 months prior to the Baseline Visit.
11. Participants who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit.
12. Participants having primary hypoactive sexual desire. 13. Participants with a history of malignancy. 14. Participate itself are not planning to get pregnant for next six months 15. Participants who cannot cooperate to complete the subject records during the study.
KSM-66 Ashwagandha root extract
Dietary Supplement: KSM-66 Ashwagandha® capsule
Starch
Other: Identical Placebo capsule
Two off-white capsules, each containing 300 mg KSM-66 Ashwagandha root extract powder only.
Two off-white capsules containing starch powder only
To evaluate the effects of the KSM-66 Ashwagandha formulation on sexual health in healthy women, assessed based on Female Sexual Function Index (FSFI) in healthy women
Mean change in FSFI scores from Visit 1 (Screening Visit/ Enrolment Visit/ Baseline Visit- Day 1), Visit 2 (Week 4) to Visit 3- End of study (Week 8) in healthy women
Time frame: Baseline, Week 4, Week 8
To evaluate the effects of the KSM-66 Ashwagandha formulation on sexual health in healthy women, assessed based on the Satisfying Sexual Events (SSEs) in healthy women
Mean change in SSEs from Visit 1 (Screening Visit/ Enrolment Visit/ Baseline Visit- Day 1), Visit 2 (Week 4) to Visit 3- End of study (Week 8) in healthy women
Time frame: Baseline, Week 4, Week 8
To evaluate the effects of the KSM-66 Ashwagandha formulation on sexual health in healthy women, assessed based on the Female Sexual Distress Scale (FSDS) in healthy women
Mean change in FSDS scores from Visit 1 (Screening Visit/ Enrolment Visit/ Baseline Visit- Day 1), Visit 2 (Week 4) to Visit 3- End of study (Week 8) in healthy women
Time frame: Baseline, Week 4, Week 8
To investigate the effects of KSM-66 Ashwagandha formulation on serum hormones (Estrogen-E2, Progesterone, FSH, LH, Prolactin, and Testosterone) in healthy women
Mean change in serum hormones (Estrogen-E2, Progesterone, FSH, LH, Prolactin, and Testosterone) from Visit 1 (Screening Visit/ Enrolment Visit/ Baseline Visit- Day 1) to Visit 3- End of study (Week 8) in healthy women
Time frame: Baseline, Week 4, Week 8
To evaluate the effects of KSM-66 Ashwagandha formulation on stress using the Perceived Stress Scale (PSS-10)
Mean change in PSS-10 scores from Visit 1 (Screening Visit/ Enrolment Visit/ Baseline Visit- Day 1), Visit 2 (Week 4) to Visit 3- End of study (Week 8) in healthy women
Time frame: Baseline, Week 4, Week 8
To evaluate the effect of the KSM-66 Ashwagandha formulation on Quality of Life (SF-12 QoL) in healthy women
Mean change in SF-12 scores from Visit 1 (Screening Visit/ Enrolment Visit/ Baseline Visit- Day 1), Visit 2 (Week 4) to Visit 3- End of study (Week 8) in healthy women
Time frame: Baseline, Week 4, Week 8
To evaluate the safety of KSM-66 Ashwagandha formulation in healthy women
Number and proportion of Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Event (TESAE) over 8 weeks treatment period
Time frame: Baseline, Week 4, Week 8
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SF Research Institute, Inc.